NYSE: BHCBausch Health Companies Inc Stock
$5.30-0.21 (-3.81%)
Updated Apr 30, 2025
BHC Price
$5.30
Fair Value Price
N/A
Market Cap
$1.95B
52 Week Low
$3.96
52 Week High
$9.85
P/E
-40.77x
P/B
-1.52x
P/S
0.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.63B
Earnings
-$46.00M
Gross Margin
71.1%
Operating Margin
16.43%
Profit Margin
-0.5%
Debt to Equity
-20.99
Operating Cash Flow
$2B
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BHC Overview
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BHC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BHC
Ranked#22 of 57
Ranked#22 of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.66 | A | |
| $32.48 | A | |
| $26.90 | A |
Be the first to know about important BHC news, forecast changes, insider trades & much more!
BHC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BHC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BHC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BHC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BHC's Earnings (EBIT) of $1.58B... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BHC due diligence checks available for Premium users.
Valuation
BHC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-40.77x
Industry
21.23x
Market
29.18x
BHC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.52x
Industry
2.09x
BHC's financial health
Profit margin
Revenue
$2.6B
Net Income
$93.0M
Profit Margin
3.6%
BHC's Earnings (EBIT) of $1.58B... subscribe to Premium to read more.
Interest Coverage Financials
BHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.5B
Liabilities
$26.8B
Debt to equity
-20.99
BHC's short-term liabilities ($6.75B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BHC's long-term liabilities ($20.09B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BHC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$601.0M
Investing
-$200.0M
Financing
$85.0M
BHC's operating cash flow ($1.60B)... subscribe to Premium to read more.
Debt Coverage Financials
BHC vs Pharmaceutical Stocks
Bausch Health Companies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.